journal article·2025-10

Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization

Jae Min Jung, Min Sang Lee, Young Kyu Seo, Jung Eun Lee, Su Yeon Lim, Dahwun Kim, Siyan Lyu, Chaeeun Park, Byung Deok Kim, Ju Hwa Shin, Ji Hyun Lee, Pin Liu, Junku Jung, João Conde, Thavasyappan Thambi, Ji Hoon Jeong, Doo Sung Lee

Biomaterials· Volume 321
Publisher page

Abstract

Recent outbreaks and the global spread of infectious diseases increased the need for the development of mucosal vaccines because of their ability to induce both an antigen-specific humoral and cellular immune response. Vaccines are commonly administered via a systemic route which is ineffective at inducing mucosal immunity. Therefore, developing mucosal vaccines is necessary to prevent and treat diseases that could not only elicit mucosal immune responses but also facilitate mass vaccination via a needle-free approach. Despite the benefits of mucosal vaccines, inducing mucosal immunity remains difficult due to the low antigen stability at mucosal sites. Herein, we developed a co-delivery platform using a polymeric nanoparticle carrier to upregulate the immune responses by improving the antigen's stability. Through hydrophobic and ionic interactions, the cationic polymeric nanoparticle composed of secondary bile acid conjugated polyethyleneimine (DA3) can load both TLR7/8 agonist resiquimod (R848) and anionic ovalbumin (OVA) antigen. The DA3/R848/OVA nanovaccine based co-delivery system can boost immune responses through binding affinity with dendritic cells (DCs). The results showed that DA3/R848/OVA could activate DCs better than OVA or OVA + R848. Furthermore, the nanovaccine demonstrated a strong therapeutic effect by significantly suppressing tumor growth in a B16-OVA melanoma model. Additionally, prophylactic immunization with the nanovaccine effectively induced immunological memory, leading to sustained tumor suppression upon challenge. Intranasal delivery of DA3/R848/OVA upregulates the antitumor effect in the metastatic lung tumor foci and the survival rates. These results suggest that intranasal immunization using the DA3/R848/OVA nanovaccine can promote needle-free vaccination.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Cancer Research and Treatments · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. Mucosal vaccines: the promise and the challenge10.1038/nri1777 ↗
2. Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity10.1016/j.celrep.2020.02.111 ↗
3. Mucosal vaccines — fortifying the frontiers10.1038/s41577-021-00583-2 ↗
4. Recent progress in mucosal vaccine development: potential and limitations10.1038/nri3251 ↗
5. Mucosal vaccines: strategies and challenges10.1016/j.imlet.2019.10.013 ↗
6. Mucosal vaccine delivery: a focus on the breakthrough of specific barriers10.1016/j.apsb.2022.07.002 ↗
7. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge10.1016/j.biomaterials.2022.121907 ↗
8. Mucosal vaccination via the respiratory tract10.3390/pharmaceutics11080375 ↗
9. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern10.1038/s41423-022-00929-3 ↗
10. An inhaled bioadhesive hydrogel to shield non-human Primates from SARS-CoV-2 infection10.1038/s41563-023-01475-7 ↗
11. Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses10.1038/s41598-020-63998-2 ↗
12. Artificial cell membrane polymersome-based intranasal beta spike formulation as a second generation Covid-19 vaccine10.1021/acsnano.2c06350 ↗
13. Biomineralized vaccine nanohybrid for needle-free intranasal immunization10.1016/j.biomaterials.2016.08.035 ↗
14. Gold-nanostar-chitosan-mediated delivery of SARS-CoV-2 DNA vaccine for respiratory mucosal immunization: development and proof-of-principle10.1021/acsnano.1c05002 ↗
15. Self-assembled flagella protein nanofibers induce enhanced mucosal immunity10.1016/j.biomaterials.2022.121733 ↗
16. Biomaterials for intranasal and inhaled vaccine delivery10.1038/s44222-022-00012-6 ↗
17. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains10.1073/pnas.2024998118 ↗
18. Intranasal subunit vaccination strategies employing nanomaterials and biomaterials10.1021/acsbiomaterials.0c01291 ↗
19. Mucosal vaccines: strategies and challenges10.1016/j.imlet.2019.10.013 ↗
20. Challenges in mucosal vaccines for the control of infectious diseases10.1093/intimm/dxu063 ↗
21. The use of viral vectors in vaccine development10.1038/s41541-022-00503-y ↗
22. Antigen-presenting, self-assembled protein nanobarrels as an adjuvant-free vaccine platform against influenza virus10.1021/acsnano.1c04078 ↗
23. Advances in chemical protein modification10.1021/cr500399p ↗
24. Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis10.1038/s41598-019-43139-0 ↗
25. Delivery of foreign antigens by engineered outer membrane vesicle vaccines10.1073/pnas.0805532107 ↗
26. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy10.1126/sciadv.adc8738 ↗
27. Delivering all in one: antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation10.1016/j.jconrel.2018.09.008 ↗
28. In situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy10.1021/acsnano.2c06560 ↗
29. Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses10.1016/j.jconrel.2020.06.021 ↗
30. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses10.1038/s41420-020-0284-1 ↗
31. HPV-Associated oropharyngeal cancer: epidemiology, molecular biology and clinical management10.1038/s41571-022-00603-7 ↗
32. Delivery of STING agonists for adjuvanting subunit vaccines10.1016/j.addr.2021.114020 ↗
33. Construction of VSVΔ51M oncolytic virus expressing human interleukin-1210.3389/fmolb.2023.1190669 ↗
34. P. Koirala, S.-P.R. Chen, J.C. Boer, Z.G. Khalil, C. Deceneux, G. Goodchild, L. Lu, M.O. Faruck, A.O. Shalash, S. Bashiri, R.J. Capon, W.M. Hussein, M.J. Monteiro, M. Plebanski, I. Toth, M. Skwarczynski, Polymeric nanoparticles as a self-adjuvanting peptide vaccine delivery system: the role of shape, Adv. Funct. Mater. n/a(n/a) 2209304.
35. Caveolin-mediated endocytosis of the chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells10.1016/j.biomaterials.2017.12.019 ↗
36. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
37. Cationic pH-Responsive polycaprolactone nanoparticles as intranasal antigen delivery system for potent humoral and cellular immunity against recombinant tetravalent dengue antigen10.1021/acsabm.9b00597 ↗
38. Key roles of adjuvants in modern vaccines10.1038/nm.3409 ↗
39. Nanotechnology-assisted immunoengineering for cancer vaccines10.1002/anbr.202200080 ↗
40. Strategies to enhance drug absorption via nasal and pulmonary routes10.3390/pharmaceutics11030113 ↗
41. Bile acid transporter-mediated oral drug delivery10.1016/j.jconrel.2020.07.034 ↗
42. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator10.1016/j.jconrel.2019.06.003 ↗
43. Mesoporous silica nanoparticles as pH-Responsive carrier for the immune-activating drug resiquimod enhance the local immune response in mice10.1021/acsnano.0c08384 ↗
44. Co-delivery of dual toll-like receptor agonists and antigen in Poly(Lactic-Co-Glycolic) acid/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses10.3389/fimmu.2017.01077 ↗
45. Thin-film hydration preparation method and stability test of DOX-loaded disulfide-linked polyethylene glycol 5000-lysine-di-tocopherol succinate nanomicelles
46. Ultrasound-enhanced siRNA delivery using magnetic nanoparticle-loaded chitosan-deoxycholic acid nanodroplets10.1002/adhm.201601246 ↗
47. Method and its composition for encapsulation, stabilization, and delivery of siRNA in anionic polymeric nanoplex: an in vitro- in vivo assessment10.1038/s41598-019-52390-4 ↗
48. Rapid agarose gel electrophoretic mobility shift assay for quantitating protein: RNA interactions10.1016/j.ab.2016.07.027 ↗
49. The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation10.1371/journal.pone.0052586 ↗
50. A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee10.1016/j.jtho.2020.06.001 ↗
51. Single-step purification of ovalbumin from egg white using aqueous biphasic systems10.1016/j.procbio.2016.03.002 ↗
52. Mucus models to evaluate the diffusion of drugs and particles10.1016/j.addr.2017.11.001 ↗
53. Positively charged nanocomplex modulates dendritic cell differentiation to enhance Th1 immune response10.1016/j.mtbio.2022.100480 ↗
54. Evolution of toll-like receptor 7/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants10.1016/j.addr.2021.05.013 ↗
55. A brief history of T cell help to B cells10.1038/nri3803 ↗
56. TLR7 and TLR8 as targets in cancer therapy10.1038/sj.onc.1210913 ↗
57. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells10.1038/leu.2016.352 ↗